ALK and non-small cell lung carcinoma: Additionally, most oncogene-driven NSCLC tumours initially responding to targeted therapies such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) and anaplastic lymphoma kinase (ALK) inhibitors eventually progress over time as they acquire drug resistance [8, 9].